The global Dry Eye Syndrome Treatment Market was valued at USD 6.7 billion in 2025 and is projected to grow from USD 7.1 billion in 2026 to USD 11.1 billion by 2033, registering a CAGR of 6.6% from 2026 to 2033. North America dominated the market with the largest revenue share of 40.3% in 2025, driven by a high prevalence of dry eye disease, strong healthcare infrastructure, growing awareness, and widespread adoption of advanced ophthalmic therapies.

The market is witnessing steady growth due to the increasing incidence of dry eye syndrome associated with prolonged digital screen exposure, aging populations, environmental pollution, and changing lifestyles. The growing dependence on smartphones, computers, tablets, and other digital devices has significantly increased the occurrence of digital eye strain, leading to greater demand for effective dry eye treatments across both developed and emerging economies.

According to a study published in India Today in July 2024, nearly 90% of school-going children are suspected to have mild to severe dry eye disease, with average daily screen time exceeding 3 to 3.5 hours. This growing digital exposure is contributing to a substantial rise in ophthalmic disorders and increasing the need for preventive eye care and long-term treatment solutions.

Advancements in pharmaceutical formulations, novel drug therapies, preservative-free artificial tears, and minimally invasive treatment technologies are further supporting market expansion while improving patient outcomes and treatment adherence.

Digital Lifestyles and Innovative Therapies Driving Market Growth

Dry eye syndrome has become one of the most frequently diagnosed ophthalmic conditions worldwide, with lifestyle changes playing a significant role in its increasing prevalence.

According to a BMC Ophthalmology article published in June 2022, the prevalence of Digital Eye Strain (DES) ranges between 5% and 50% globally, with higher rates observed among women and older adults. Increasing screen exposure, reduced blinking frequency, air-conditioned environments, and prolonged visual tasks continue to contribute to the rising burden of dry eye disease.

Modern treatment innovations include:

• Preservative-free artificial tears
• Lipid-based ophthalmic formulations
• Anti-inflammatory prescription therapies
• Intense Pulsed Light (IPL) therapy
• Meibomian gland dysfunction treatments
• Thermal pulsation devices
• Advanced diagnostic imaging
• Personalized ocular surface management

Among these innovations, Intense Pulsed Light (IPL) therapy has emerged as a promising non-invasive treatment option. Each session typically lasts 15–20 minutes, with four to five sessions often providing sustained relief from dry eye symptoms. Increasing patient preference for long-lasting treatments that reduce dependence on frequent eye drop application is expected to support continued adoption of IPL and other device-based therapies.

Download a free sample copy of the Dry Eye Syndrome Treatment Market report to understand detailed coverage and inclusions in the final report

Emerging Industry Trend: Personalized Ocular Surface Care

One of the most significant developments in the dry eye syndrome treatment market is the shift toward personalized treatment strategies. Ophthalmologists are increasingly using advanced diagnostic technologies to evaluate tear film quality, meibomian gland function, ocular surface inflammation, and blinking behavior, allowing therapies to be tailored according to the underlying cause of dry eye disease. This precision-based approach is improving treatment effectiveness while enhancing long-term patient satisfaction.

Key Market Trends & Insights

Evaporative Dry Eye Syndrome Leads the Market

• By type, the evaporative dry eye syndrome segment accounted for the largest revenue share of 82.6% in 2025.
• Evaporative dry eye is the most common form of the condition and is primarily associated with dysfunction or blockage of the meibomian glands.
• Patients frequently experience symptoms including grittiness, burning sensations, blurred vision, contact lens intolerance, and eye fatigue due to increased tear evaporation.

Artificial Tears Continue to Dominate Product Demand

• By product, the artificial tears segment held the largest revenue share of 43.7% in 2025 and is also expected to register the fastest growth during the forecast period.
• Ease of use, patient comfort, and continuous innovation in preservative-free formulations continue driving widespread adoption.
• Ongoing research into next-generation artificial tear products is further strengthening market growth. For example, in May 2024, ophthalmic surgeon Eric Donnenfeld presented clinical findings for Blink Triple Care at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).

Other Drugs Segment Maintains Market Leadership

• By drugs, the other drugs segment accounted for the largest revenue share of 91.3% in 2025.
• Broad product availability, affordability, and effective symptom management continue supporting strong demand.
• Strategic pharmaceutical acquisitions are also strengthening this segment. In September 2023, Bausch + Lomb acquired Xiidra from Novartis to expand its dry eye disease treatment portfolio.

Eye Drops Remain the Preferred Dosage Form

• By dosage form, the eye drops/solutions segment held the largest revenue share of 64.9% in 2025.
• Frequent product approvals and innovative ophthalmic formulations continue expanding treatment options.
• In January 2022, Sun Pharmaceutical Industries Ltd. introduced CEQUA 0.09%, a cyclosporine ophthalmic solution developed for dry eye disease treatment.

Prescription Drugs Lead Sales Channel

• By sales channel, the prescription drugs segment accounted for the largest revenue share of 51.6% in 2025.
• Prescription therapies remain the preferred treatment option for moderate to severe dry eye disease due to their proven clinical efficacy and physician supervision.
• Growing disease prevalence among older adults continues to support long-term prescription demand.

Looking for more specific insights? Customize this report to suite your business needs

Retail Pharmacies Dominate Distribution

• By distribution channel, the retail channel accounted for the largest revenue share of 55.5% in 2025.
• High accessibility, favorable reimbursement policies, and pharmacist-led patient education continue driving retail pharmacy sales.
• Retail pharmacies remain the primary point of access for prescription ophthalmic medications in many healthcare systems.

Regional Highlights

• Largest Regional Market: North America (40.3% revenue share, 2025)
• Fastest Growing Regional Market: Asia Pacific (Highest CAGR, 2026–2033)
• Leading Country: United States

North America continues to dominate due to high diagnosis rates, advanced ophthalmology infrastructure, and strong adoption of innovative treatment technologies. Meanwhile, Asia Pacific is expected to witness the fastest growth owing to increasing digital device usage, expanding healthcare access, aging populations, and rising awareness regarding ocular health across emerging economies.

Market Size & Forecast

• Market Size (2025): USD 6.7 Billion
• Estimated Market Size (2026): USD 7.1 Billion
• Projected Market Size (2033): USD 11.1 Billion
• CAGR (2026–2033): 6.6%

Competitive Landscape

Leading companies in the dry eye syndrome treatment market continue investing in research and development, innovative drug formulations, advanced ophthalmic devices, and strategic acquisitions to strengthen their competitive positions.

Key strategic priorities include:

• Development of next-generation ophthalmic therapies
• Preservative-free artificial tear formulations
• Expansion of prescription treatment portfolios
• Device-based dry eye therapies
• Personalized ocular surface management
• Strategic acquisitions and licensing agreements
• Global commercialization initiatives

These investments are expected to improve treatment accessibility while addressing the growing global burden of dry eye disease.

Explore Grand View Horizon to see global and regional level statistics related to the Dry Eye Syndrome Treatment Market

Key Dry Eye Syndrome Treatment Companies

The following companies are among the leading participants operating in the global dry eye syndrome treatment market:

• Novartis AG
• AbbVie, Inc.
• Sun Pharmaceutical Industries Ltd.
• Santen Pharmaceutical Co. Ltd.
• AFT Pharmaceuticals
• Johnson & Johnson Services, Inc.
• Otsuka Pharmaceutical Co., Ltd. (subsidiary of Otsuka Holdings Co., Ltd.)
• OASIS Medical
• Oyster Point Pharma, Inc. (acquired by Viatris Inc. in January 2023)
• Bausch Health Companies, Inc.

Conclusion

The dry eye syndrome treatment market is poised for steady growth as rising digital screen exposure, aging populations, environmental factors, and increasing awareness continue to drive demand for effective ocular therapies. Ongoing innovation in artificial tears, prescription medications, non-invasive treatment technologies, and personalized diagnostic approaches is reshaping patient care and improving long-term clinical outcomes. As healthcare providers increasingly adopt precision-based treatment strategies and patients seek convenient, long-lasting symptom relief, the market is expected to maintain sustained growth through 2033. Companies that prioritize innovation, advanced drug development, patient-centered care, and global market expansion will be well-positioned to capitalize on the evolving opportunities within the dry eye syndrome treatment industry.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments
• Extended forecast timelines for long-term planning
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…